Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > FGEN FibroGen > Detailed Quotes

FGEN FibroGen

Watchlist
13.305
+0.045+0.34%
Trading Session 09/30 13:12 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
13.550
Open
13.190
Turnover
2.55M
Low
13.100
Pre Close
13.260
Volume
191.45K
Market Cap
1.25B
P/E(TTM)
Loss
52wk High
16.910
Shares
93.74M
P/E(Static)
Loss
52wk Low
7.810
Float Cap
1.09B
Bid/Ask %
-50.00%
Historical High
68.550
Shs Float
82.28M
Volume Ratio
0.49
Historical Low
7.810
Dividend TTM
--
Div Yield TTM
--
P/B
12.02
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.23%
Amplitude
3.39%
Avg Price
13.336
Lot Size
1
Float Cap
1.09B
Bid/Ask %
-50.00%
Historical High
68.550
Shs Float
82.28M
Volume Ratio
0.49
Historical Low
7.810
Dividend TTM
--
P/B
12.02
Dividend LFY
--
Turnover Ratio
0.23%
Amplitude
3.39%
Avg Price
13.336
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
CEO: Conterno, Enrique A.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top